Biotech RadarJobs updated

COMPANY

DiaMedica Therapeutics

HQ: Minneapolis, MN source · diamedica.com ↗ · Midwest

Clinical Phase 3

Keywords: ischemia Stroke Acute Stroke Ischemic Stroke Pre-Eclampsia Acute Ischemic Stroke Kidney Diseases Chronic Kidney Disease Diabetes Diabetes Type 2 Recombinant human tissue kallikrein DM199

Location: Minneapolis, MN · source · Aug 10, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

  1. Trial start Not phased (device or behavioral study): DM199 for Pregnancy Complications source ↗
  2. Trial start Phase 2/Phase 3: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) source ↗
  3. Trial start Phase 2: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) source ↗
  4. Trial start Phase 1: Study to Assess PK, Safety and Tolerability in Patients With DM and CKD source ↗
  5. Trial start Phase 2: Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke source ↗
  6. Trial start 1: An Open Label, Phase 1b, Ascending Dose Study of DM199 source ↗
  7. Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT05065216Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)Phase 2/Phase 3RecruitingNov 7, 20212026-12 (estimated)
NCT06875141DM199 for Pregnancy ComplicationsNot phased (device or behavioral study)Withdrawn2025-052025-05 (estimated)
NCT03290560Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic StrokePhase 2CompletedJan 19, 2018Jan 23, 2020 (actual)
NCT04123613Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)Phase 2CompletedDec 17, 2019Mar 16, 2022 (actual)
NCT03795389Study to Assess PK, Safety and Tolerability in Patients With DM and CKDPhase 1CompletedFeb 12, 2019Jul 21, 2019 (actual)
NCT02868996An Open Label, Phase 1b, Ascending Dose Study of DM1991Completed2016-092017-03 (actual)
NCT01845064A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes PatientsPhase 1/Phase 2Completed2013-042014-09 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback